KORU Medical Systems, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $148.2M
- Price
- $3.21
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.83%
- Volume
- 235.2K
About
KORU Medical Systems, Inc. designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. It offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company also provides education and training materials to clinicians, patients, and patient advocates. It sells its products through direct sales and medical device distributors, as well as online. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York.
Quick stats
Shares outstanding46.2M
Computed float37.5M
Float / shares81.1%
Key info
SectorHealthcare
IndustryMedical - Instruments & Supplies
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000704440
Websitehttps://www.korumedical.com
AI Summary
AI-generated1/16
majorbullishearnings
KORU Medical Systems Announces Second Quarter 2026 Results and Updates Full Year 2026 Guidance
KORU Medical Systems reported Q2 2026 revenue of $12.0 million, up 18.2% year-over-year, driven by volume gains in both domestic and international core markets. The company achieved profitability with net income of $0.25 million and positive adjusted EBITDA of $0.9 million, marking a significant operational inflection.
Management executed a strategic pivot by withdrawing its 510(k) application for FreedomEDGE with Phesgo to focus on higher-volume molecules, while simultaneously acquiring a connected monitoring technology asset. A new multi-year supply agreement was also established to support long-term margin expansion.
The company updated full-year 2026 guidance, narrowing revenue expectations to $47.5 million to $48.5 million and raising gross margin targets to 62% to 64%. Cash balance stood at $8.3 million at the end of the quarter.
Red flags
- Pharma services and clinical trials revenue declined 35% year-over-year
- Withdrew 510(k) application for FreedomEDGE with Phesgo in the U.S. to shift strategy